Bilateral angle-closure glaucoma secondary to selective serotonin reuptake inhibitor

Peter Cackett*, J. R. Cameron, B. Morris, E. Scoppettuolo, J. Singh

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Background: Depression is a common illness with significant morbidity and mortality with antidepressants frequently being prescribed by general practitioners. Tricyclic antidepressants are well known to precipitate angle-closure glaucoma via their anticholinergic effects but more recently there have been reports of selective serotonin reuptake inhibitors also giving rise to episodes of angle-closure glaucoma. Case presentation: We describe the case of a 73-year-old woman who developed an attack of bilateral angle-closure glaucoma shortly after taking her first dose of paroxetine. Presentation was delayed because the patient was unaware of the potential for paroxetine to have ophthalmic side effects. Conclusions: Hopefully, with an increased awareness of this problem, patients will present earlier with a consequent decrease in ocular morbidity.

Original languageEnglish
Pages (from-to)387-388
Number of pages2
Issue number3
Publication statusPublished - 20 Jun 2006

Keywords / Materials (for Non-textual outputs)

  • Angle closure
  • Glaucoma
  • Selective serotonin reuptake inhibitor


Dive into the research topics of 'Bilateral angle-closure glaucoma secondary to selective serotonin reuptake inhibitor'. Together they form a unique fingerprint.

Cite this